{
    "nct_id": "NCT05958199",
    "official_title": "A Phase 1a/1b, Dose-Escalation/Dose-Expansion Study of NPX267 in Subjects With Solid Tumors Known to Express HHLA2/B7-H7",
    "inclusion_criteria": "* Histologically or cytologically confirmed recurrent, metastatic solid tumor refractory to standard of care therapy in one of the following indications: Part 1a: non-small cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma (CRC), cholangiocarcinoma (CCA), pancreatic cancer (PDAC), urothelial carcinoma (UCC), gastric/gastroesophageal carcinoma, triple negative breast carcinoma, endometrial carcinoma, cervical cancer, osteosarcoma, and prostate cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Normal bone marrow, kidney and liver function\n* Willing to use highly effective contraceptive measures throughout the trial\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Have any unresolved toxicity of Grade â‰¥ 2 from previous anti-cancer treatment, except for alopecia, chronic neuropathy > 6 months, or changes in skin pigmentation\n* Have known or suspected brain metastases, unless they are clinically stable\n* Known autoimmune disease requiring immunosuppressive treatment requiring the equivalent of more than 10 mg prednisone daily\n* History of grade 3 immune-related pneumonitis or colitis",
    "miscellaneous_criteria": ""
}